Pfizer Inc.
PFEHealthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −9.68%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) EV/FCF
As of Nov 19, 2026, Pfizer Inc. (PFE) trades at a EV/FCF of 18.7×. Over the past ten years it has ranged from 8.4× (October 2021) to 59.9× (July 2024); the current reading is higher than 56% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 23.3× | 8.38% |
| FY2024 | 21.5× | (62.19%) |
| FY2023 | 56.8× | 377.05% |
| FY2022 | 11.9× | 2.42% |
| FY2021 | 11.6× | (42.98%) |
| FY2020 | 20.4× | (19.27%) |
| FY2019 | 25.3× | 26.50% |
| FY2018 | 20.0× | 22.69% |
| FY2017 | 16.3× | 4.34% |
| FY2016 | 15.6× | 0.52% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 19.2× | 3.63% |
| Jun 2026 | 18.5× | (23.81%) |
| Mar 2026 | 24.3× | 4.44% |
| Dec 2025 | 23.3× | 16.40% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.4× |
| GSK GSK PLC Sponsored ADR compare | 14.0× |
| BMY Bristol Myers Squibb Company compare | 16.1× |
| GILD Gilead Sciences, Inc. compare | 16.4× |
| PFE Pfizer Inc. | 18.7× |
| NVS Novartis AG compare | 22.9× |
| NVO Novo Nordisk A/S compare | 26.8× |
| AMGN Amgen Inc. compare | 30.4× |
| AZN AstraZeneca PLC compare | 46.6× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement